What are the prospects for antiplatelet agents for thromboprophylaxis in antiphospholipid syndrome?

Click to increase image sizeClick to decrease image size

Declaration of interest

M Khamashta is an employee of GSK and holds stocks and shares in the company. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers in this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.